PATENT
Docket No. 219002030901

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

George F. SCHREINER, *et al.*

Serial No.: 10/083,817

Filing Date: 26 February 2002

For: METHODS OF TREATING HYPERTENSION AND COMPOSITIONS FOR USE THEREIN

Examiner: Christine J. Saoud

Group Art Unit: 1647

DECLARATION OF GEORGE F. SCHREINER, M.D., PH.D.

UNDER 37 C.F.R. § 1.132

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

I, George F. Schreiner, declare as follows:

1. I am Senior Vice President of Scios Research & Development and Chief Scientific & Medical Officer at Scios, Inc., the assignee of the present application. I hold a M.D. from Harvard Medical School and a Ph.D. in Immunology from Harvard University. I have been working in the field of cardiovascular disease and nephrology for over 24 years. A copy of my *curriculum vitae* is attached (Exhibit 3).

2. In accordance with standard procedures recognized as significant by workers in the field of hypertension, the effect of administering vascular endothelial growth factor to animals presenting elevated blood pressure as a result of the expression of the VEGF receptor sFlt(1-3) was observed as described below.

3. An adenovirus was engineered to express the soluble VEGF receptor sFlt(1-3). This construct expresses the first three IgG-like domains of sFlt-1. The expressed portion of the

receptor includes the VEGF binding domain but omits domains 4-6, which include the regions responsible for receptor dimerization. A schematic of Flt-1 and the soluble form, sFlt-1, is shown in Exhibit 1A. Sequence analysis of the mouse and human Flt-1 and sFlt-1 at the truncation site that makes the receptor soluble is shown in Exhibit 1B.

4. The engineered adenovirus was used to infect a control group and a treated group, with six rats in each group. Both groups were injected in the tail vein with 1×10^9 plaque forming units (pfu) of the adenovirus engineered to express sFlt(1-3). On the second day after viral injection, animals were randomized to receive $VEGF_{121}$ (100 mg/kg body weight) or phosphate buffered saline (PBS) subcutaneously twice a day for 7 days. On the 7th day after the morning VEGF injection, animals were cannulated for blood pressure measurement and blood was drawn. Plasma samples were analyzed for the presence of sFlt(1-3) and to detect free VEGF using an ELISA assay (data not shown).

5. Blood pressure measurements were taken from the animals in each group. Rats have a resting systolic pressure of about 120 mmHg and a resting diastolic pressure of about 84 mmHg. As shown in Exhibit 2, animals in the control group had elevated systolic and diastolic blood pressures. Animals treated with VEGF showed reduced blood pressure relative to the control group. The blood pressure measurements from the control group of rats approached normal levels. . All rats involved in the study were maintained on a diet of standard rat chow, which is low in dietary salt.

6. The results provided above demonstrate that VEGF is a useful in lowering blood pressure in an animal model of hypertension that is not salt-dependent.

I declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements are made with the knowledge that willful, false statements and the like so made are punishable by fine or imprisonment or both, under Section 1001 of Title 18 of the United States

Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Executed at Raritan, NJ on 01 03 2004.
(city) (state) (day) (month)

George F. Schreiner, M.D., Ph.D.

EXHIBIT 1


A
Extracellular region
Intracellular region
Flt-1
1 2 3 4 5 6 7
sFlt-1
1 2 3 4 5 6
Plasma membrane
B
Exon 13
Exon 14
Intron 13
Mouse
Flt-1
sFlt-1
Human sFlt-1
650 R K T E Y L V R D S E A P H L L Q M L S D
CGGAAGACAGAAGTTCTCGTTAGAG ATTCGGAAGCGCCACACCTGCTTCAAAACCTCAGTGAC
CGGAAGACAGAAGTTCTCGTTAGAG GTGAGCACTGCGGCAAAAAGGCCATTTTCTCTCGGATC
650 R K T E Y L V R G E H C G K K A I F S R I
649 Q - K - I T I - - - - - H - - - V - - - -
671 Y E V S I S G S T T L D C Q A R G V P A P Q
TACGAGGTCTCCATCAGTGGCTCTACGACCTTAGACTGTCAAGCTAGAGGTGTCCCGCCGCCTCAG
TCCAAATTTAAAAGCAGGAGGAATGATTGTACCACACAAAGTCATGTCAAACATTAAAGGACTCAT
671 S K F K S R R M D C T T Q S H V K H *
670 - - - - - T - - - - - - - - N - - - *

EXHIBIT 2


Blood Pressure (mm Hg)
180
160
140
120
100
80
60
Systoli
Diastoli
Control
VEGF
Mean +/- SEM

George F. Schreiner

12774 Leander Drive
Los Altos Hills, CA 94022
(650)-941-5123

EDUCATION

1971	A.B.	Harvard College, Cambridge, Massachusetts
1977	M.D.	Harvard Medical School, Boston, Massachusetts
1977	Ph.D.	Harvard University, Cambridge, Massachusetts (Immunology)

PROFESSIONAL EXPERIENCE

8/00-
Scios Inc.
CHIEF SCIENTIFIC OFFICER AND VICE PRESIDENT

Responsibilities: (a) All research operations, including medicinal chemist
(b) Preclinical development of drug candidates
(c) Strategic clinical development of novel drug candidates
(d) Development of new indications for currently marketed drugs

1/97-8/00
Scios Inc.
VICE PRESIDENT OF CARDIORENAL RESEARCH
CORPORATE MANAGEMENT COMMITTEE

Responsibilities: (a) Established disease-based research program focusing on inflammation, cardiac and pulmonary diseases, and progressive renal failure.
(b) Technical supervision of functional genomics, molecular and cellular biology, pharmacology, pathology, high throughput screening, preclinincal development.
(b) Established focus on small molecule kinase inhibitors and recombinant protein therapeutics

1/95-1/97
CV Therapeutics Inc.
VICE PRESIDENT, MEDICAL SCIENCE AND PRECLINICAL RESEARCH

1/933-1/95
CV Therapeutics Inc
VICE PRESIDENT, MEDICAL SCIENCE

ACADEMIC APPOINTMENTS

1980-1982	Instructor in Pathology, Department of Pathology, Harvard Medical School, Boston, Massachusetts
1982-1985	Assistant Professor of Pathology, Department of Pathology, Harvard Medical School, Boston, Massachusetts
1983-1985	Assistant Professor of Medicine, Brigham and Women's Hospital Harvard Medical School, Boston, Massachusetts
1985-1989	Assistant Professor of Medicine and Pathology Washington University School of Medicine St. Louis, Missouri
1989-1993	Associate Professor of Medicine and Pathology Washington University School of Medicine St. Louis, Missouri
1993-1997	Consulting Professor of Medicine, Stanford University Palo Alto, California

POSTDOCTORAL TRAINING

1977-1980	Medical Resident, Peter Bent Brigham Hospital, Boston, Massachusetts
1982-1983	Fellow, Renal Division, Brigham and Women's Hospital, Boston, Massachusetts

RESEARCH FELLOWSHIPS

1973-1974	Fellow, Karen Grunebaum Foundation
1977-1980	Research Fellow, Department of Pathology, Harvard Medical School, Boston, Massachusetts
1980-1982	Fellow, Arthritis Foundation

CERTIFICATION

American Board of Medicine
Internal Medicine
Nephrology

HONORS/AWARDS/OFFICES

1985	Established Investigator, American Heart Association
1989-1990	Chairman, Midwest Section, American Federation for Clinical Research
1989-1990	Co-Chairman, Public Policy Committee, American Federation for Clinical Research
1990	American Society for Clinical Investigation
1991-1992	Chairman, Public Policy Committee, American Federation for Clinical Research
1992	Member, Council on Glomerular Diseases, National Kidney Foundation
1991-1996	Assistant Editor, American Journal of Kidney Diseases

HOSPITAL APPOINTMENTS

1980-1985	Junior Associate in Medicine, Brigham and Women's Hospital, Boston, Massachusetts
1986-1993	Associate Physician, Barnes Hospital, St. Louis, Missouri
1986-1988	Assistant Director of the Renal Transplant Service, Department of Medicine, Barnes Hospital, St. Louis, Missouri

MEMBERSHIPS IN PROFESSIONAL SOCIETIES

1978	American Association of Immunologists
1982	The American Society of Nephrology
1982	American Society of Pathologists
1983	International Society of Nephrology
1987	American Federation for Clinical Research
1988	National Kidney Foundation
1990	American Society for Clinical Investigation

PATENTS

US 5,631,260	Xanthine epoxides as A.Sub.1 adenosine receptor agonists and antagonists
US 5,663,450	Macrophage lipid chemoattractant
US 5,668,139	A1 adenosine receptor agonists and antagonists
US 5,789,416	N.sup.6 mono heterocyclic substituted adenosine derivatives
US 5,840,875	Kidney Na/PO.sub.4 cotransporter antisense oligonucleotide
US 5,869,537	Macrophage lipid chemoattractant
US 6,130,235	Compounds and methods to treat cardiac failure and other disorders
US 6,184,226	Quinazoline derivatives as inhibitors of p-38 alpha.
US 6,277,989	Quinazoline derivatives as medicaments
US 6,340,685	Compounds and methods to treat cardiac failure and other disorders
US 6,342,495	Agonists and antagonists of peripheral-type benzodiazepine receptors
US 6,352,975	Methods of treating hypertension and compositions for use therein
US 6,380,183	Treatment of diseases involving cyst formation
US 6,410,540	Inhibitors of p38 alpha kinase
US 6,340,685 B1	Compounds to treat cardiac failure
US 6,541,477 B2	Inhibitors of p38-alpha kinase
US 6,589,954 B1	Compounds and methods to treat cardiac failure and other disorders
US 6,677,300 B1	Treatment of Microvascular Angiopathies

Patents Pending: 7

PUBLICATIONS

1. Schreiner, G.F. and Unanue, E.R. 1975. The modulation of spontaneous and anti-Ig-stimulated motility of lymphocytes by cyclic nucleotides and adrenergic and cholinergic agents. *J. Immuno.* 114(2 Pt 2):802-808.
2. Unanue, E.R. and Schreiner, G.F. 1975. The modulation of immunoglobulin in B lymphocytes and its relevance to immune stimulation. In: Rosenthal, A.S., ed. Immune Recognition. New York, New York: Academic Press, Inc. p. 261-280.
3. Unanue, E.R., Ault, K.A., Schreiner, G.F. and Sidman, C.L. 1975. The cycle of ligand-induced changes in B cells-functional relationship. In: Seligmann, M., Preud'homme, J.L., Kourilsky, F.M., eds. Membrane Receptors of Lymphocytes. Amsterdam, Holland: North-Holland Publishing Company, p.363-372.
4. Schreiner, G.F. and Unanue, E.R. 1975. Anti-Ig-triggered movement of lymphocytes: specificity and lack of evidence for directional migration. *J. Immuno.* 114(2 Pt 2):809-814.
5. Schreiner, G.F. and Unanue, E.R. 1976. Membrane and cytoplasmic changes in B lymphocytes induced by ligand-surface immunoglobulin interactions. *Adv. Immuno.* 24:37-165.
6. Schreiner, G.F. and Unanue, E.R. 1976. Calcium-sensitive modulation of Ig capping: evidence supporting a cytoplasmic control of ligand-receptor complexes. *J. Exp. Med.* 143(1):15-31.
7. Schreiner, G.F and Unane, E.R. 1976. The disruption of immunoglobulin caps by local anesthetics. *Clin. Immunol. Immunopathol.* 6(2):264-269.
8. Schreiner, G.F., Braun, J. and Unanue, E.R. 1976. Spontaneous redistribution of surface immunoglobulin in the motile B lymphocyte. *J. Exp. Med.* 114:1683-1688.
9. Unanue, E.R. and Schreiner, G.F. 1977. Structure and function of surface immunoglobulin of lymphocytes. In: Poste, G. and Nicolson, G. eds., Dynamic Aspects of Cell Surface Organization. Elsevier/North-Holland Biomedical Press. p.619-641.
10. Schreiner, G.F., Fujiwara, K., Pollard, T.D. and Unanue, E.R. 1977. Redistrubution of myosin accompanying capping of surface lg. *J. Exp. Med.* 145(5):1393-1398.
11. Ward, P.A., Unanue, E.R., Goralnick, S. and Schreiner, G.F. 1977. Chemotaxis of rat lymphocytes. *J. Immunol.* 119(2):416-421.
12. Schreiner, G.F. and Unanue, E.R. 1977. Capping and the lymphocyte: models for membrane reorganization. *J. Immunol.* 119(5):1549-1551.
13. Schreiner, G.F., Cotran, R.S., Pardo, V. and Unanue, E.R. 1978. A mononuclear cell component in experimental immunological glomerulonephritis. *J. Exp. Med.* 147(2):367-384.
14. Schreiner, G.F. 1979. Membrane and cytoplasmic correlates of initial lymphocyte activation. *J. Reticuloendothe Soc.* 26:719-726.
15. Schreiner, G.F., Cotran, R.S. and Unanue, E.R. 1981. Glomerular cells and immune function. In: Zurukzoglu, W., Papdimitriou, M., Pyrpasopoulos, M., Sion, M., Zamboulis, C., eds. Proceedings of the Eight International Congress of Nephrology: Advances in Basic and Clinical Nephrology. Basel, Switzerland: S. Karger. 858.
16. Schreiner, G.F., Kiely, J.M, Cotran, R.S. and Unanue, E.R. 1981. Characterization of resident glomerular cells in the rat expressing Ia determinants and manifesting genetically restricted interactions with lymphocytes. *J. Clin. Invest.* 68(4):920-921.

17. Unanue, E.R., Schreiner, G.F. and Cotran, R.S. 1982. A role of mononuclear phagocytes in immunologically induced glomerulonephritis. In: Cummings, N., Michael, A., Wilson, C., Immune Mechanisms in Renal Disease. New York, NY: Plenum Publishing Corporation. 443-445.
18. Schreiner, G.F., Cotran, R.S. and Unanue, E.R. 1982. Macrophages and cellular immunity in experimental glomerulonephritis. *Springer Seminars in Immunopathol.* 5(3):251-267.
19. Schreiner, G.F. and Cotran, R.S. 1982. Localization of an Ia-bearing glomerular cell in the mesangium. *J. Cell Biol.* 94(2):483-488.
20. Schreiner, G.F. and Unanue, E.R. 1984. Origin of the rat mesangial phagocyte and its expression of the leukocyte common antigen. *Lab Invest.* 51(5):515-523.
21. Schreiner, G.F., Cotran, R.S and Unanue, E.R. 1984. Modulation of Ia and leukocyte common antigen expression in rat glomeruli during the course of glomerulonephritis and aminonucleoside nephrosis. *Lab. Invest.* 51(5):524-533.
22. Schreiner, G.F. and Abbas, A.K. 1984. Cells and tissues of immune responses. Cerny, J., Barron, S., Medical Microbiology. New York, NY, p. 31.
23. Lefkowith, J.B. and Schreiner, G.F. 1987. Essential fatty acid deficiency depletes rat glomeruli of resident macrophages and inhibits angiotensin II-induced eicosanoid synthesis. *J. Clinic. Invest.* 80(4):947-956.
24. Gulick T., Chung, M.K., Pieper, S.J. Schreiner, G.F. and Lange, L.G. 1988. Immune cytokine inhibition of beta-adrenergic agonist stimulated cyclic AMP generation in cardiac myocytes. *Biochem. Biophys. Res. Comm.* 150(1):1-9.
25. Schreiner, G.F., Flye, W., Brunt, E., Korber, K. and Lefkowith, J.B. 1988. Essential fatty acid depletion of renal allografts and prevention of rejection. *Science.* 240(4855):1032-1033.
26. Kohan, D.E. and Schreiner, G.F. 1988. Interleukin 1 modulation of renal epithelial glucose transport. *Am. J. Physiol.* 254(6 Pt 2):F879-F886.
27. Badr, K.F., Schreiner, G.F., Wasserman, M. and Ichikawa, I. 1988. Preservation of the glomerular capillary ultrafiltration coefficient during rat nephrotoxic serum nephritis by a specific leukotriene D4 receptor antagonist. *J. Clin. Invest.* 81(6):1702-1709.
28. Klahr, S., Schreiner, G.F. and Ichikawa, I. 1988. The progression of renal disease. *New Eng. J. Med.* 318(25):1657-1666.
29. Wright, J.R., Lefkowith, J.B., Schreiner, G.F. and Lacy, P.E. 1988. Essential fatty acid deficiency prevents multiple low-dose streptozotocin-induced diabetes in CD-1 mice. *Proc. Natl. Acad. Sci.* 85(16):6137-6141.
30. Schreiner, G.F., Harris K., Purkerson, M. and Kahr, S. 1988. Immunological aspects of acute ureteral obstruction: immune cell infiltrate in the kidney. *Kid. Int.* 34(4):487-493.
31. Lefkowith, J., Morrison, A. and Schreiner, G.F. 1988. Murine glomerular leukotriene by synthesis: Manipulation by (n-6) fatty acid deprivation and cellular origin. *J. Clin. Invest.* 82(5):1655-1660.
32. Passwell, J., Schreiner, G.F., Nonaka, M., Beuscher, H.U. and Colten, H.R. 1988. Local extrahepatic expression of complement genes C3, Factor B, C2 and C4 is increased in murine lupus nephritis. *J. Clin. Invest.* 82(5):1676-1684.
33. Lefkowith, J.B., Roving, B. and Schreiner, G.F. 1989. Depletion of resident glomerular macrophages by essential fatty acid deficiency protects against glomerulonephritis. In: Adv. Prostaglandin Thromboxane and Leukotriene Res. 19:560-563, Samuelson B., Sun, F., and Wong, P. eds., Raven Press Ltd., New York.

34. Harris, K., Schreiner, G.F. and Klahr, S. 1989. Effect of leukocyte depletion on the function of the postobstructed kidney in the rat. *Kid Int.* 36:210-215.
35. Gulick, T., Chung, M.K., Pieper, S.J., Lange, L.G. and Schreiner, G.F. 1989. Interleunin-1 and tumor necrosis factor inhibit cardiac myocyte beta-adrenergic responsiveness. *Proc. Nat. Acad. Sci.* 86(17):6753-6757.
36. Schreiner, G.F. and Kissane, J. 1989. The urinary system. In Anderson's Pathology, Kissane, J. ed., C. Mosby and Co., St. Louis, p. 804-871.
37. Schreiner, G.F., Rovin, B. and Lefkowith, J.B. 1989. The anti-inflammatory effects of essential fatty acid deficiency in experimental glomerulonephritis: the modulation of macrophage migration and eicosanoid metabolism. *J. Immuno.* 143(10):3192-3199.
38. Schreiner, G.F. 1990. Pathways leading from glomerular injury to glomerulosclerosis. *Contrib. Nephrology.* 86:1-18.
39. Lefkowith, J., Schreiner, G.F., Cormier, J., Handler, E.S., Driscol, H.K., Greiner, D., Mordes, J.P., and Rossini, A.A. 1989. Prevention of diabetes in the BB rat by essential fatty acid deficiency: Relationship between physiological and biochemical changes. *J. Exp. Med.* 171(3):729-743.
40. Schreiner, G.F. and Kohan, D. 1990. Regulation of renal transport processes and hemodynamics by macrophages and lymphocytes. *Am. J. Physiol.* (Renal Fluid Electrolyte Physiol. 27) 258(4 Pt 2): F761-F767.
41. Takahaski, K., Schreiner, G.F., Yamashita, K., Christman, B.W., Blair, I. and Badr, K.F. 1990. Predominant functional roles for thromboxane A_2 and prostaglandin E_2 during late nephrotoxic serum glomerulonephritis in the rat. *J. Clin. Invest.* 85(6):1974-1982.
42. Rovin, B.H., Harris, K.P., Morrison, A., Klahr, S. and Schreiner, G.F. 1990. Renal cortical release of a specific macrophage chemoattractant in response to ureteral obstruction. *Lab Invest.* 63(2):213-220.
43. Rovin, B.H., Lefkowith, J.B and Schreiner, G.F. 1990. Mechanisms underlying the anti-inflammatory effects of essential fatty acid deficiency in experimental glomerulonephritis: Inhibited release of a monocyte chemoattractant by glomeruli. *J. Immuno.* 145(4):1238-1245.
44. Chung, M.K., Gulick, T.S., Rotondo, R.E., Schreiner, G.F. and Lange, L.G. 1990. Mechanism of cytokine inhibition of beta-adrenergic agonist stimulation of cAMP in rat cardiac myocytes: Impairment of signal transduction. *Circulation Res.* 67(3):753-763.
45. Harris, K., Lefkowith, J., Klahr, S. and Schreiner, G.F. 1990. Essential fatty acid deficiency ameliorates acute renal dysfunction in the rat after the administration of the aminonucleoside of puromycin. *J. Clin. Invest.* 86(4):1115-1123.
46. Passwell, J.H., Schreiner, G.F., Wetsel, R.A. and Colten, H.R. 1990. Complement gene expression in hepatic and extrahepatic tissues of NZB and NZBxW (FI) mouse strains. *J. Immuno.* 71(2):290-294.
47. Modi, K.S., Morrissey, J., Shah, S.V., Schreiner, G.F. and Klahr, S. 1990. Effects of probucol on renal function in rats with bilateral ureteral obstruction. *Kid. Int.* 38(5):843-850.
48. Dusso, A.S., Finsch, J., Brown, A., Ritter, C., Delmez, J., Schreiner, G.F. and Slatopolsky, E. 1991. Extrarenal production of calcitriol in normal and uremic humans. *J. Clin. Endoc. Metab.* 72(1):157-165.
49. Rovin, B.H. and Schreiner, G.F. 1990. Cell-mediated immunity in glomerular disease. *Ann. Rev. Med.* 42:25-33.

50. Greenwald, J.E., Needleman, P., Wilkins, M. and Schreiner, G.F. 1991. Renal synthesis of atriopeptin-like protein in physiology and pathophysiology. *Am. J. Physiol.* 260(4 Pt 2):F602-F607.
51. Hait, W.N. and Schreiner, G.F. 1991. The AFCS's public policy efforts—overview and outlook. *Clin Res.* 39(2):169-172.
52. Schreiner, G.F. 1991. Dietary treatment of immunologically mediated renal disease. *Kidney Int. Suppl.* 31:S49-56.
53. Schreiner, G.F. and Klahr, S. 1991. Diet and kidney disease: the role of dietary fatty acids. *Proc. Soc. Exp. Biol. Med.* 197(1):1-11.
54. Schreiner, G.F. 1991. The role of the macrophage in glomerular injury. *Semin. Nephrol.* 11(3):268-275.
55. Udey, M.D., Peck, R.D., Pentland, A.P., Schreiner, G.F. and Lefkowith, J.B. 1991. Antigen-presenting cells in essential fatty acid-deficient murine epidermis: keratinocytes bearing class II (Ia) antigens may potentiate the accessory cell function of Langerhans cells. *J. Invest. Dermatol.* 96(6):950-958.
56. Gulick T., Pieper, S.J., Murphy, M.A., Lange, L.G. and Schreiner, G.F. 1991. A new method for assessment of cultured cardiac myocyte contractility detects immune factor-mediated inhibition of beta-adrenergic responses. *Circulation.* 84(1):313-321.
57. Schreiner, G.F. and Rovin B. 1991. The role of dietary fatty acids in progressive renal disease. In: Lipids and Renal Disease, p. 149-177. W. Keane, ed., Churchill Livingstone, Inc. New York, NY.
58. Harris, K.P.G., Yanagisawa, H., Schreiner, G.F. and Klahr, S. 1991. Evidence for two distinct and functionally important sites of enhanced thromboxane production after bilateral ureteral obstruction. *Clin. Sci.* 81(2):209-213.
59. Klahr, S., Harris, K.P.G. and Schreiner, G.F. 1991. Role of the immune system in obstructive uropathy in Tubulo-Interstitial Nephropathies, p. 169-186. Fourth Bari Seminar in Nephrology. Edited by A. Amerio, P. Corrateli, and S.G. Massry. Kluwer Academic Publishers, Boston.
60. Lefkowith, J.B., Pippin, J. and Schreiner, G.F. 1991. Role of leukocytes in the metabolic and functional derangements of experimental glomerulonephritis. *Am. J. Physiol.* 261(2 Pt 2):F213-F220.
61. Muir, A., Rovin, B., Lacy, P. and Schreiner G.F. 1991. Macrophage-specific chemotactic lipid release by in vivo streptozotocin-administered mouse islets. *Diabetes.* 40(11):1459-1466.
62. Lange, L. and Schreiner, G.F. 1992. Immune cytokines and cardiac disease. *Trends in Cardiovascular Medicine.* 2:145-151.
63. Schreiner, G.F. 1992. The mesangial phagocyte and its regulation of contractile cell biology. *J. Am. Soc. Nephrol.* 2(10 Suppl):S74-82.
64. Porras-Reyes, B.H., Schreiner, G.F., Lefkowith, J.B., Markham, H. and Mustoe, T.A. 1992. Essential fatty acids are not required for wound healing. *Prostaglandins Leukot. Essent. Fatty Acids.* 45(4):293-298.
65. Takahaski, K., Kato T., Schreiner, G.F. and Badr, K. 1992. Essential fatty acid deficiency completely normalized microvascular hemodynamics and glomerular histology throughout the course of experimental glomerulonephritis in the rat. *Kid. Int.* 41(5):1245-1253.

66. Modi, K.S., Schreiner, G.F., Purkerson, M.L. and Klahr, S. 1992. Effects of probucol in renal function and structure in rats with subtotal kidney ablation. *J. Lab. Clin. Med.* 120:310-317.
67. Nagamatsu, T., Pippin, J. Schreiner, G.F. and Lefkowith, J.B. 1992. Paradoxical exacerbation of leukocyte-mediated glomerulonephritis with cyclooxygenase inhibition. *Am. J. Physiol.* 263(2 Pt 2):F228-236.
68. Thomas, M.E. and Schreiner, G.F. 1993. Contribution of proteinuria to progressive renal injury: consequences of tubular uptake of fatty acid bearing albumin. *Am. J. Nephrol.* 13(5)385-398.
69. Harris, K.P.G., Klahr, S. and Schreiner, G.F. 1993. Obstructive nephropathy; from mechanical disturbance to immune activation? *Experimental Nephrology.* 1:198-204.
70. Schreiner, G.F., Kamei, T., Lefkowith, J. and Flye, M.W. 1993. Modulation of the kinetics of the initial leukocyte migration into renal allografts and by 16, 16-dimethyl PGE2. *Transplantation.* 56(2):417-422.
71. Schreiner, G.F. 1993. Progression of glomerular sclerosis: Molecular and immunologic mechanisms. In: Nephrology and Urology in the Aged Patient, D. Oreopoulos, ed., Kluwer Academic Publishers, Dordrecht. pp. 49-56.
72. Lange, L. and Schreiner, G.F. 1994. Immune mechanism of cardiac disease. *New Eng. J. Med.* 45:1697-1709.
73. Kees-Folts, D., Sadow, J. and Schreiner, G.F. 1994. Tubular catabolism of albumin is associated with the release of an inflammatory lipid. *Kid. Int.* 45(6):1129-1135.
74. van Goor, H., Ding, G., Kees-Folts, D., Grond, J., Schreiner, G. F. and Diamond, J. R. 1994. Biology of disease macrophages and renal disease. *Laboratory Investigation.* 71(4):456-464.
75. Klahr, S., Martin, K.J., Kelmez, J.A. and Schreiner, G.F. 1995. Progress report: The AJKD matures. *Am. J. Kidney Dis.* 25(1):1-2.
76. Thomas, M.E., Morrison, A. R. and Schreiner, G. F. 1995. Metabolic Effects of fatty acid bearing albumin on a proximal tubule cell line. *Am. J. Physiol.* 37:F1177-1184.
77. Schreiner, G.F. 1995. Renal toxicity of albumin and other lipoproteins. *Curr. Opin. Nephrol Hypertens.* 4(4):369-373.
78. Oberbauer, R., Schreiner, G.F. and Meyer, T. W. 1995. Renal uptake of an 18-mer phosphorothioate oligonucleotide. *Kid. Int.* 48: 1226-1232.
79. Schreiner, G.F. In Press. The Nephrotic Syndrome. In: Medicine for the Practicing Physician, J. Willis Hurst, M.D., ed., Appleton & Lange, Simon & Schuster Publishing, Connecticut.
80. Schreiner, G. F. 1995. Renal toxicity of albumin and other lipoproteins. *Curr. Opin. Nephro.l Hypertens.* 4(4):369-373.
81. Oberbauer, R., Murer, H., Schreiner, G.F. and Meyer, T.W. 1996. Antisense and the kidney. *Kidney Blood Press Res.* 19(5):221-224.
82. Oberbauer, R., Schreiner, G.F., Biber, J., Murer, H. and Meyer, T. 1996. In vivo suppression of the renal Na/Pi cotransporter by antisense oligonucleotides. *Proc. Natl. Acad. Sci. USA.* 93:4903-4906
83. Pfister, J.R., Belardinelli, L., Lee,G., Lum, R.T ., Milner, P., Stanley, W.C., Linden, J., Baker, S.P. and Schreiner, G.F. 1997. Synthesis and biological evaluation of the enantiomers of the potent and selective A1-adenosine antagonist 1,3-dipropyl-8-(2-(5,6-epoxynorbonyl))-xanthine. *J. Med. Chem.* 40:1773-1778.

84. Grantham, J.J. Schreiner, G.F., Rome, L., Grenz, L. and Joly, A. 1997. Evidence for inflammatory and secretagogue lipids in cyst fluids from patients with autosomal dominant polycystic kidney disease. *Proc. Assoc. Am. Physicians*. 109(4):397-408.
85. Johnson, R. and Schreiner, G.F. 1997. Hypothesis: The role of acquired tubulointerstitial disease in the pathogenesis of salt-dependent hypertension. *Kid. Int.* 52(5):1169-1179.
86. Oberbauer, R., Schreiner, G.F. and Meyer, T.W. 1998. Natriuretic effect of adenosine A1-receptor blockade in rats. *Nephrol. Dial. Transplant.* 13(4):900-903.
87. Schreiner, G.F. 1998. Immune modulation of cardiac cell function. *Trans. Am. Clin. Climatol. Assoc.* 109:39-50.
88. Gellai, M., Schreiner, G.F., Ruffolo, R.R., Fletcher, T., Dewolf, R. and Brooks, D.P. 1998. CVT-124, a novel adenosine A1 receptor antagonist with unique diuretic activity. *J. Pharm .Exp. Therap.* 286(3):1191-1196.
89. Wilcox, C., Welch, W., Schreiner, G.F. and Belardinelli, L. 1999. Natriuretic and diuretic actions of a highly selective adenosine A1 receptor antagonist. *J. Am. Soc. Nephrol.* 10(4):714-720.
90. Lindner, A., Hinds, T., Joly, A. and Schreiner, G. 1999. Neutral lipid from proteinuric rat urine is a novel inhibitor of the red blood cell calcium pump. *J. Am. Soc. Nephrol.* 10(6):1170-1178.
91. Stanton, L.W., Garrard, L.J., Damm, D., Garrick. B.L., Lam, A., Kapoun, A.M., Zheng, Q., Protter, A.A., Schreiner, G.F. and White, R.T. 2000. Altered patterns of gene expression in response to myocardial infarction. *Circ. Res.* 86(9):939-945.
92. Taylor, L.A., Carthy, C.M., Yang, D., Saad, K., Wong, D., Schreiner, G.F., Stanton, L.W. and McManus, B.M. 2000. Host gene regulation during coxsackievirus B3 infection in mice: assessment by microarrays. *Circ. Res.* 87:328-334.
93. Chen, M.M., Lam, A., Abraham, J.A., Schreiner, G.F. and Joly, A.H. 2000. CTGF expression is induced by TGF-beta in cardiac fibroblasts and cardiac myocytes: a potential role in heart fibrosis. *J. Mol. Cell Cardiol.* 323:1805-1819.
94. Kim, Y.G., Suga, S.I., Kang, D.H., Jefferson, J.A., Mazzali, M., Gordon, K.L., Matsui, K., Breiteneder-Geleff, S., Shankland, S.J., Hughes, J., Kerjaschki, D., Schreiner, G.F. and Johnson, R.J. 2000. Vascular endothelial growth factor accelerates renal recovery in experimental thrombotic microangiopathy. *Kidney Int.* 58:2390-2399.
95. Henson, M., Damm, D., Lam, A., Garrard, L.J., White, T., Abraham, J.A., Schreiner, G.F., Stanton, L.W. and Joly, A.H. 2001. Insulin-like growth factor-binding protein-3 induces fetalization in neonatal rat cardiomyocytes. *DNA Cell Biol.* 12:757-7630.
96. Kang, D.H., Anderson, S., Kim, Y.G., Mazzalli, M., Suga, S., Jefferson, J.A., Gordon, K.L., Oyama, T.T., Hughes, J., Hugo, C., Kerjaschki, D., Schreiner, G.F. and Johnson, R.J. 2001. Impaired angiogenesis in the aging kidney: vascular endothelial growth factor and thrombospondin-1 in renal disease. *Am. J. Kidney Dis.* 37:601-611.
97. Kang, D.H., Kim, Y.G., Andoh, T.F., Gordon, K.L., Suga, S., Mazzali, M., Jefferson, J.A., Hughes, J., Bennett, W., Schreiner, G.F. and Johnson, R.J. 2001. Post-cyclosporine-mediated hypertension and nephropathy: amelioration by vascular endothelial growth factor. *Am. J. Physiol. Renal Physiol.* 280:F727-736.
98. Kang, D.H., Joly, A.H. Oh, S.W., Hugo, C. Kerjaschi, D., Gordon, K.L., Mazzali, M., Jefferson, J.A., Hughes, J., Madsen, K.M., Schreiner, G.F. and Johnson, R.J. 2001. Impaired angiogenesis in the remnant kidney model: I. Potential role of vascular endothelial growth factor and thrombospondin-1. *J. Am. Soc. Nephrol.* 12:1434-1447.

99. Kang, D.H., Hughes, J., Mazzali, M., Schreiner, G.F. and Johnson, R.J. 2001. Impaired angiogenesis in the remnant kidney model: II. Vascular endothelial growth factor administration reduces renal fibrosis and stabilizes renal function. *J. Am. Soc. Nephrol.* 12:1448-1457.
100. Suga, S., Kim, Y.G., Joly, A., Puchacz, E., Kang, D.H., Jefferson, J.A., Abraham, J.A., Hughes, J., Johnson, R.J. and Schreiner, G.F. 2001. Vascular endothelial growth factor (VEGF121) protects rats from renal infarction in thrombotic microangiopathy. *Kidney Int.* 60:1297-1308.
101. Feng, Y, Schreiner, G.F., Charkavarty, S., Liu, D.Y. and Joly, A.H. 2001. Inhibition of the mitogen activated protein kinase, p38 alpha, prevents proinflammatory cytokine induction by human adherent mononuclear leukocytes in response to lipid loading. *Atherosclerosis*. 158:331-338.
102. Villanueva, F.S, Abraham, J.A., Schreiner, G.F., Csikari, M., Fischer, D., Mills, J.D., Schellenberger, U., Koci, B.J. and Lee, J.S. 2002. Myocardial contrast echocardiography can be used to assess the microvascular response to vascular endothelial growth factor-121. *Circulation.* 105:759-765.
103. Kang, D.H., Kanellis, J., Hugo, C., Truong, L., Anderson, S., Kerjaschki, D., Schreiner, G.F. and Johnson, R.J. 2002. Role of the microvascular endothelium in progressive renal disease. *J Am Soc Nephrol.* 13(3):806-816.
104. Schreiner, G.F. and Protter, A.A. 2002. B-type natriuretic peptide for the treatment of congestive heart failure. *Curr. Opin. Pharma.* 2:142-147.
105. Jefferson, J.A., Escudero, E., Hurtado, M.E., Pando, J., Tapia, R., Swenson, E.R., Prchal, J., Schreiner, G.F., Schoene, R.B., Hurtado, A. and Johnson, R.J. 2002. Excessive erythrocytosis, chronic mountain sickness, and serum cobalt levels. *Lancet.* 359(9304):407-408.
106. Johnson, R.J., Herrera-Acosta, J., Schreiner, G.F. and Rodriguez-Iturbe, B. 2002. Subtle acquired renal injury as a mechanism of salt-sensitive hypertension. *New Eng. J. Med.* 346(12):913-923.
107. Kim, Y.G., Suga, S.I., Kang, D.H., Jefferson, J.A., Mazzali, M., Gordon, K.L., Matsui, K., Breiteneder-Geleff, S., Shankland, S.J., Hughes, J., Kerjaschki, D., Schreiner, G.F. and Johnson, R.J. 2000. Vascular endothelial growth factor accelerates renal recovery in experimental thrombotic microangiopathy. *Kidney Int.* 58:2390-2399.
108. Henson, M., Damm, D., Lam, A., Garrard, L.J., White, T., Abraham, J.A., Schreiner, G.F., Stanton, L.W. and Joly, A.H. 2001. Insulin-like growth factor-binding protein-3 induces fetalization in neonatal rat cardiomyocytes. *DNA Cell Biol.* 12:757-7630.
109. Kang, D.H., Anderson, S., Kim, Y.G., Mazzalli, M., Suga, S., Jefferson, J.A., Gordon, K.L., Oyama, T.T., Hughes, J., Hugo, C., Kerjaschki, D., Schreiner, G.F. and Johnson, R.J. 2001. Impaired angiogenesis in the aging kidney: vascular endothelial growth factor and thrombospondin-1 in renal disease. *Am. J. Kidney Dis.* 37:601-611.
110. Kang, D.H., Kim, Y.G., Andoh, T.F., Gordon, K.L., Suga, S., Mazzali, M., Jefferson, J.A., Hughes, J., Bennett, W., Schreiner, G.F. and Johnson, R.J. 2001. Post-cyclosporine-mediated hypertension and nephropathy: amelioration by vascular endothelial growth factor. *Am. J. Physiol. Renal Physiol.* 280:F727-736.
111. Kang, D.H., Joly, A.H. Oh, S.W., Hugo, C. Kerjaschi, D., Gordon, K.L., Mazzali, M., Jefferson, J.A., Hughes, J., Madsen, K.M., Schreiner, G.F. and Johnson, R.J. 2001. Impaired angiogenesis in the remnant kidney model: I. Potential role of vascular endothelial growth factor and thrombospondin-1. *J. Am. Soc. Nephrol.* 12:1434-1447.

112. Kang, D.H., Hughes, J., Mazzali, M., Schreiner, G.F. and Johnson, R.J. 2001. Impaired angiogenesis in the remnant kidney model: II. Vascular endothelial growth factor administration reduces renal fibrosis and stabilizes renal function. *J. Am. Soc. Nephrol.* 12:1448-1457.
113. Suga, S., Kim, Y.G., Joly, A., Puchacz, E., Kang, D.H., Jefferson, J.A., Abraham, J.A., Hughes, J., Johnson, R.J. and Schreiner, G.F. 2001. Vascular endothelial growth factor (VEGF121) protects rats from renal infarction in thrombotic microangiopathy. *Kidney Int.* 60:1297-1308.
114. Feng, Y, Schreiner, G.F., Charkavarty, S., Liu, D.Y. and Joly, A.H. 2001. Inhibition of the mitogen activated protein kinase, p38 alpha, prevents proinflammatory cytokine induction by human adherent mononuclear leukocytes in response to lipid loading. *Atherosclerosis.* 158:331-338.
115. Villanueva, F.S, Abraham, J.A., Schreiner, G.F., Csikari, M., Fischer, D., Mills, J.D., Schellenberger, U., Koci, B.J. and Lee, J.S. 2002. Myocardial contrast echocardiography can be used to assess the microvascular response to vascular endothelial growth factor-121. *Circulation.* 105:759-765.
116. Kang, D.H., Kanellis, J., Hugo, C., Truong, L., Anderson, S., Kerjaschki, D., Schreiner, G.F. and Johnson, R.J. 2002. Role of the microvascular endothelium in progressive renal disease. *J Am Soc Nephrol.* 13(3):806-816.
117. Schreiner, G.F. and Protter, A.A. 2002. B-type natriuretic peptide for the treatment of congestive heart failure. *Curr. Opin. Pharma.* 2:142-147.
118. Jefferson, J.A., Escudero, E., Hurtado, M.E., Pando, J., Tapia, R., Swenson, E.R., Prchal, J. Schreiner, G.F., Schoene, R.B., Hurtado, A. and Johnson, R.J. 2002. Excessive erythrocytosis, chronic mountain sickness, and serum cobalt levels. *Lancet.* 359(9304):407-408.
119. Johnson, R.J., Herrera-Acosta, J., Schreiner, G.F. and Rodriguez-Iturbe, B. 2002. Subtle acquired renal injury as a mechanism of salt-sensitive hypertension. *New Eng. J. Med.* 346(12):913-923.
120. Jefferson, J.A., Escudero, E., Hurtado, M.E., Kelly, J.P., Swenson, E.R., Wener, M.H., Burnier, M., Baillard, M., Schreiner, G.F., Schoene, R.B., Hurtado, A. and Johnson, R.J. 2002. Hyperuricemia, hypertension, and proteinuria associated with high-altitude polycythemia. *Am J. Kidney Dis.* 39(6):1135-1142.
121. Johnson, R.J., Rodriguez-Iturbe, B., Schreiner, G.F. and Herrera-Acosta, J. 2002. Hypertension: a microvascular and tubulointerstitial disease. *J. Hypertension.* Suppl 3:S1-7.
122. McManus, B.M., Yanagawa, B., Rezai, N., Luo, H., Taylor, L., Xhang, M., Yuan, J., Buckley, J., Tricke, T., Schreiner, G. and Yang, D. 2002. Genetic determinants of coxsackievirus B3 pathogenesis. *Ann. N.Y. Acad. Sci.* 975:169-179.
123. Stambe, C., Atkins, R.C., Tesch, G.H., Kapoun, A.M., Hill, P.A., Schreiner, G.F. and Nikolic-Paterson, D.J. 2002. Blockade of p38alpha MAPK ameliorates acute inflammatory renal injury in rat anti-GBM glomerulonephritis. *J. Am. Soc. Nephrol.* 14(2):338-351.
124. Lu, E.X., Wagner W.R.; Schellenberger, U.; Abraham, J.A.; Klibanov, A.L.; Woulfe, S.R.; Csikari, M.M.; Fischer, D.; Schreiner, G.F.; Brandenburger, G.H.; Villanueva, F.S. 2003. Targeted *in vivo* labeling of receptors for vascular endothelial growth factor - Approach to identification of ischemic tissue. *Circulation.* 108:97-103.

125. Kanellis, J., Nakagawa, T., Herrera-Acosta, J., Schreiner, G.F., Rodriguez-Iturbe, B., Johnson, R.J. 2003. A single pathway for the development of essential hypertension. *Cardiol Rev.* 11(14):180-196.
126. Mavunkel, B.J., Chakravarty, S., Perumattam, J.J., Luedtke, G.R., Liang, X., Lim, D., Xu, Y., Laney, M. Liu, D.Y., Schreiner, G.F., Lewicki, J.A., Dugar, S. 2003. Indole-based heterocyclic inhibitors of p38alpha MAP kinase: designing a conformationally restricted analogue. *Bioorg Med Chem Lett.* 13(18):3087-3090.